An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

Myeloma remains incurable with conventional treatment in the vast majority of patients. The introduction of thalidomide in 1999 for the treatment of relapsed disease offers the opportunity to treat patients who have developed myelotoxicity or who are refractory to conventional chemotherapy. The opti...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2003-10, Vol.27 (10), p.909-914
Main Authors: Schey, S.A., Cavenagh, J., Johnson, R., Child, J.A., Oakervee, H., Jones, R.W.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Disease-Free Survival
Female
Follow-Up Studies
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulinopathies
Immunopathology
Male
Maximum Tolerated Dose
Medical sciences
Middle Aged
Multiple myeloma
Multiple Myeloma - complications
Multiple Myeloma - drug therapy
Multiple Myeloma - mortality
Pharmacology. Drug treatments
Practice Guidelines as Topic
Relapsed disease
Remission Induction
Salvage Therapy
Survival Rate
Thalidomide
Thalidomide - administration & dosage
Thalidomide - toxicity
Treatment recommendations
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myeloma remains incurable with conventional treatment in the vast majority of patients. The introduction of thalidomide in 1999 for the treatment of relapsed disease offers the opportunity to treat patients who have developed myelotoxicity or who are refractory to conventional chemotherapy. The optimal schedule remains unresolved and only two studies have reported long term follow-up data. We report a phase II low dose escalation study of thalidomide with long term follow-up showing overall survival (OS) of 19 months and progression free survival (PFS) of 14 months. In addition we report on the side effects and toxicity and give recommendations for the use of thalidomide in the relapsed setting based upon these findings.
ISSN:0145-2126
1873-5835
DOI:10.1016/S0145-2126(03)00027-4